Research Topics
| A J GarberSummaryAffiliation: Baylor College of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Premixed insulin analogues for the treatment of diabetes mellitusAlan J Garber
Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Drugs 66:31-49. 2006..In addition, given the convenience of mealtime dose administration, compliance with insulin therapy may increase with premixed insulin analogues...- Obesity and type 2 diabetes: which patients are at risk?A J Garber
Departments of Medicine, Biochemistry and Molecular Biology, and Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
Diabetes Obes Metab 14:399-408. 2012..By viewing obesity as a metabolic disorder rather than a personal weakness, we can work with patients to address this increasingly prevalent condition and improve long-term health outcomes... - Postprandial dysmetabolism and the heartAlan J Garber
Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, 1709 Dryden Road, Houston, TX 77030, USA
Heart Fail Clin 8:563-73. 2012..Pharmacotherapies that target postprandial hyperglycemia and/or postprandial dyslipidemia are likely to improve endothelial function, which may have positive implications for cardiovascular outcomes... - Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trialAlan J Garber
Baylor College of Medicine, Houston, TX, USA
Lancet 379:1498-507. 2012..Insulin degludec is a new, ultra-longacting basal insulin. We aimed to assess efficacy and safety of insulin degludec compared with insulin glargine in patients with type 2 diabetes mellitus... - Liraglutide in oral antidiabetic drug combination therapyA J Garber
Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA
Diabetes Obes Metab 14:13-9. 2012..While further study will be required, GLP-1 receptor agonists may offer important advantages over other diabetic therapies, including DPP-4 inhibitors... - Cardiovascular risk and diabetes mellitus management: diagnosis and treatment in special patient populations. IntroductionAlan J Garber
Department of Medicine, Baylor College of Medicine, 6550 Fannin, Suite 1045, Houston, Texas 77030, USA
Am J Med 118:1S-2S. 2005 - Pharmacologic modifications of hormones to improve their therapeutic potential for diabetes managementAlan J Garber
Department of Medicine, Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
Diabetes Obes Metab 7:666-74. 2005..In summary, the development of new insulin and other hormone preparations by the manipulation of native peptide structure has recently improved our antidiabetic armamentarium, and further research will continue this fruitful approach... - Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)A J Garber
Baylor College of Medicine, Houston, TX 77030, USA
Diabetes Obes Metab 8:58-66. 2006..5 and <7%)... - Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled studyA J Garber
Division of Endocrinology, Baylor College of Medicine, Houston, TX 77030, USA
Diabetes Obes Metab 9:166-74. 2007..The purpose of this study was to assess the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor vildagliptin in combination with the thiazolidinedione (TZD) pioglitazone in patients with type 2 diabetes (T2DM)... - Premixed insulin treatment for type 2 diabetes: analogue or human?Alan J Garber
Baylor College of Medicine, Faculty Center, Houston, TX 77030, USA
Diabetes Obes Metab 9:630-9. 2007..Overall, the evidence suggests that premixed insulin analogues are cost effective and have useful advantages over premixed human insulin for the treatment of type 2 diabetes... - Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trialsAlan J Garber
Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, Texas, USA
J Am Geriatr Soc 55:1735-40. 2007..To compare the safety and efficacy of insulin detemir with that of neutral protamine Hagedorn (NPH) insulin in older (aged >/=65) and younger (aged 18-64) persons with type 2 diabetes mellitus (DM)... 
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetesA Garber
Department of Medicine and the Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, 1709 Dryden Road, Houston, TX 77030, USA
Diabetes Obes Metab 13:348-56. 2011..Most treatments for type 2 diabetes fail over time, necessitating combination therapy. We investigated the safety, tolerability and efficacy of liraglutide monotherapy compared with glimepiride monotherapy over 2 years...- The metabolic syndromeAlan J Garber
Department of Medicine, Baylor College of Medicine, 6550 Fannin Street, Suite 1045, Houston, TX 77030, USA
Med Clin North Am 88:837-46, ix. 2004..A combination of chemoprevention and lifestyle modification may prevent many if not most cases of diabetes if treatment is instituted early... - Metformin and vascular protection: a diabetologist's viewA J Garber
Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
Diabetes Metab 29:6S113-6. 2003.... - Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension studyAlan J Garber
Baylor College of Medicine, Methodist Hospital, Houston, Texas 77030, USA
Clin Ther 24:1401-13. 2002.... - Benefits of combination therapy of insulin and oral hypoglycemic agentsAlan J Garber
Baylor College of Medicine, Houston, Tex 77030, USA
Arch Intern Med 163:1781-2. 2003 - Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetesA J Garber
Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
Diabetes Obes Metab 4:201-8. 2002..To evaluate whether simultaneous initial treatment of both insulin resistance and impaired beta-cell insulin secretion with glyburide/metformin tablets is superior to monotherapy with each component agent... - Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetesAlan J Garber
Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
J Clin Endocrinol Metab 88:3598-604. 2003.... - Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetesA Garber
Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
Diabetes Obes Metab 5:171-9. 2003..25 mg, 500 mg/2.5 mg and 500 mg/5 mg), in comparison with metformin 500 mg and glibenclamide 2.5-5 mg monotherapy, in clinically important patient subgroups within the type 2 diabetic population... - The importance of early insulin secretion and its impact on glycaemic regulationA J Garber
Baylor College of Medicine, Houston, Texas 77030, USA
Int J Obes Relat Metab Disord 24:S32-7. 2000..As well as offering a more flexible approach to treatment, prandial repaglinide is associated with a reduced risk of severe hypoglycaemia... - Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylureaA J Garber
Baylor College of Medicine, Houston, TX, USA
Diabetes Obes Metab 10:1047-56. 2008..To compare the efficacy and tolerability of vildagliptin vs. placebo in patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled [haemoglobin A(1c) (HbA(1c)) 7.5 to 11%] with prior sulphonylurea (SU) monotherapy... - Diabetic dyslipidemia and the heartAbu R Vasudevan
Center for Cadiovascular Disease Prevention, Lipoprotein and Atherosclerosis Research Section, Baylor College of Medicine, Houston, TX 77030, USA
Heart Fail Clin 2:37-52. 2006 - The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin aloneRalph A DeFronzo
University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
Diabetes Care 32:1649-55. 2009..This 24-week trial assessed the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes with inadequate glycemic control with metformin alone... - Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practiceAlan J Garber
Baylor College of Medicine, Houston, Texas 77030, USA
Diabetes Obes Metab 4:S5-12. 2002..Data from the Heart Outcomes Prevention Evaluation (HOPE) trial demonstrated that CV risk can be further reduced by the addition of the ACE inhibitor ramipril to the existing treatment regimen of high-risk patients with diabetes... - Diabetes and vascular diseaseA J Garber
Vascular Disease Working Group, 6550 Fannin Street, Suite 1045, Houston, TX 77030, USA
Diabetes Obes Metab 2:S1-5. 2000..Important steps to decreasing the risk of these diseases in diabetic patients are strict glycaemic control, control of hypertension, and modification of dyslipidaemia... - Strategies for better diabetes control in the USA J Garber
Department of Medicine, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030, USA
Drugs 58:61-9. 1999..It is hoped that organised implementation of these treatment algorithms will produce better control of diabetes and its complications than the current ad hoc strategies used by individual practitioners... - Point: Inpatient glucose management: the emperor finally has clothesMichael Bryer-Ash
Gonda Diabetes Center, Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine at UCLA, 900 Veteran Ave, Suite 24-130, Los Angeles, CA 90095, USA
Diabetes Care 28:973-5. 2005 - Current standards of care for inpatient glycemic management and metabolic control: is it time for definite standards and targets?Alan J Garber
Baylor College of Medicine, Houston, Texas, USA
Endocr Pract 10:10-2. 2004..To review the available literature on the presence of diabetes in the inpatient population and its effect on outcomes... - An overview of incretin clinical trialsAlan J Garber
Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX, USA
J Fam Pract 57:S10-8. 2008..The article also discusses some of the important clinical differences between GLP-1 receptor agonists and DPP-4 inhibitors... - Role of insulin signaling in maintaining energy homeostasisMorali D Sharma
Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA
Endocr Pract 14:373-80. 2008..To examine the role that insulin signaling plays in modulating metabolic functions involving both peripheral and hypothalamic systems... - Update: vildagliptin for the treatment of Type 2 diabetesAlan J Garber
Professor of Medicine, Biochemistry and Molecular Biology, and Molecular and Cellular Biology, Baylor College of Medicine, Division of Diabetes, Endocrinology and Metabolism, 1709 Dryden, Suite 1000, Houston, TX 77030, USA
Expert Opin Investig Drugs 17:105-13. 2008..Across studies, vildagliptin was effective in reducing HbA(1c), had a low risk of hypoglycemia and was weight-neutral and well tolerated... - Treatment of dyslipidemia in diabetesA J Garber
Departments of Medicine, Biochemistry and Cell Biology, Department of Family and Community, Baylor College of Medicine, Department of Endocrinology, Diabetes, and Metabolism, Methodist Hospital, Houston, Texas, USA
Endocrinol Metab Clin North Am 30:999-1010. 2001..Statins are also the only agents thus far shown in prospective, controlled trials to reduce the risk of coronary events in diabetic patients definitively... - Insulin resistance syndrome. A reviewA R Vasudevan
Division of Endocrinology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
Minerva Endocrinol 30:101-19. 2005..The rising obesity epidemic portends great significance, as it is associated with a high prevalence of IR. We review the etiopathogenesis of IR, the clinical spectrum, and review the clinical data on the management of IR... - Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation centerJohn A Goss
Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
Transplantation 74:1761-6. 2002.... - Cardiovascular complications of diabetes: prevention and managementAlan J Garber
Baylor College of Medicine, Methodist Hospital Houston, Texas, USA
Clin Cornerstone 5:22-37. 2003..For the most part, such management has been proven to reduce CV events in patients with diabetes, particularly type 2 diabetes... - Reducing the risk of stroke through appropriate targets and treatmentsMichael H Davidson
Prev Cardiol 10:215-21. 2007.... - Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metforminEmanuele Bosi
Diabetes and Endocrinology Unit, Department of General Medicine, San Raffaele Scientific Institute, Vita Salute San Raffaele University, Milan, Italy
Diabetes Care 30:890-5. 2007..We sought to evaluate the efficacy and safety of vildagliptin, a new dipeptidyl peptidase-4 inhibitor, added to metformin during 24 weeks of treatment in patients with type 2 diabetes... - Assessing the role of biphasic insulin aspart 30 as an effective and tolerable front-line therapy for type 2 diabetesAlan J Garber
Clin Ther 27:S39-41. 2005 - New standards to reduce morbidity and mortality in hospitalized patients with diabetesAlan J Garber
Am Fam Physician 73:591, 594. 2006 - American College of Endocrinology position statement on inpatient diabetes and metabolic controlAlan J Garber
Endocr Pract 10:4-9. 2004 - American College of Endocrinology position statement on inpatient diabetes and metabolic controlAlan J Garber
Endocr Pract 10:77-82. 2004 - The metabolic syndrome: a call to actionAntonio M Gotto
Office of the Dean, Joan and Sanford I Weill Medical College of Cornell University, New York, New York, USA
Coron Artery Dis 17:77-80. 2006..While more research is needed to understand the pathology of the metabolic syndrome, there is no ambiguity that physicians should treat cardiovascular risk factors in individuals with metabolic syndrome...